Valuation: Arctic Bioscience

Market Cap 75.48M 7.84M 6.97M 6.5M 5.93M 11.18M 754M 11.28M 78.69M 30.49M 385M 29.44M 28.8M 1.24B P/E 2026 *
-3.15x
P/E 2027 * -
Enterprise Value 141M 14.7M 13.06M 12.19M 11.11M 20.95M 1.41B 21.15M 147M 57.15M 722M 55.18M 53.98M 2.32B EV / Sales 2026 *
2.44x
EV / Sales 2027 * -
Free-Float
47.75%
Yield 2026 *
-
Yield 2027 * -
1 week+2.19%
Current month+7.69%
1 month+8.11%
3 months-15.15%
6 months-15.15%
Current year-14.63%
1 week 2.47
Extreme 2.47
2.8
1 month 2.47
Extreme 2.47
2.8
Current year 2.33
Extreme 2.33
3.67
1 year 2.33
Extreme 2.33
4.2
3 years 1.65
Extreme 1.65
16.8
5 years 1.65
Extreme 1.65
21.7
10 years 1.65
Extreme 1.65
32
Manager TitleAgeSince
Chief Executive Officer 60 2010-12-31
Chief Executive Officer 54 2022-02-28
Director of Finance/CFO 47 2022-03-31
Director TitleAgeSince
Chairman 68 2015-11-30
Director/Board Member 55 2014-12-31
Director/Board Member 46 2020-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
4/24/23 Buy

Director

943,833 3.8641%
4/24/23 Buy

Director

943,833 3.8641%
2/23/23 Buy

Chief Technology Officer

11,500 0.0472%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.19%-17.65%-71.89% 7.84M
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.21%-2.49%+22.69%+44.25% 369.72B
Weighted average by Cap. +0.42%-3.33%+30.52%+68.96%

Financials

2026 *2027 *
Net sales 58M 6.03M 5.35M 5M 4.55M 8.59M 579M 8.67M 60.47M 23.43M 296M 22.62M 22.13M 950M -
Net income -24M -2.49M -2.22M -2.07M -1.88M -3.55M -240M -3.59M -25.02M -9.7M -123M -9.36M -9.16M -393M -
Net Debt 66M 6.86M 6.09M 5.69M 5.18M 9.77M 659M 9.86M 68.81M 26.66M 337M 25.74M 25.18M 1.08B -
Logo Arctic Bioscience
Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
Employees
19
Date Price Change Volume
26-10-02 NOK 2.800 0.00% 0
26-10-01 NOK 2.800 +7.69% 100
26-09-30 NOK 2.600 0.00% 3,687
26-09-29 NOK 2.600 -4.76% 287
26-09-28 NOK 2.730 -0.36% 590
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Annual profits - Rate of surprise